Andrew Weickhardt's guest appearances

Andrew Weickhardt

Talking Urology Podcast

The Do Landers

Angie Smith

Dean Karnazes

John Davis

Ronny Chieng

Steve Walsh

Chris Sweeney

Julia Gillard

Frank Gardiner

James Thornton

David Quinn

Fleur McDonald

David Gray

Sarah Bailey

Matt Keenan

Tim Reed

OwlTail

A patient once said this of Andrew Weickhardt:I'm sitting on the wings of angels in a never ending circle of bliss and joy. And it's all due to you and your spicy, clever and frightfully brilliant ways. You're the man, the dude, the chic researcher and clinician in your crisp grey suit. I love you and what you have done and do.Andrew is a leading oncologist and he uses cutting edge science and technology to both save and improve the lives of people with cancer.He has an unquenchable thirst for knowledge, he is a teacher, a leader in his field and he leads with aplomb, he is a creator hope and a mender of many. Andrew's work is inspired by his patients and the tireless team around him.Andrew's doing will inspire you.

A patient once said this of Andrew Weickhardt: I'm sitting on the wings of angels in a never ending circle of bliss and joy. And it's all due to you and your spicy, clever and frightfully brilliant ways. You're the man, the dude, the chic researcher and clinician in your crisp grey suit. I love you and what you have done and do. Andrew is a leading oncologist and he uses cutting edge science and technology to both save and improve the lives of people with cancer. He has an unquenchable thirst for knowledge, he is a teacher, a leader in his field and he leads with aplomb, he is a creator hope and a mender of many. Andrew's work is inspired by his patients and the tireless team around him. Andrew's doing will inspire you.

Ep 29: A/Prof Andrew Weickhardt: leading oncologist using cutting edge science and technology

Betsy Plimack

In this ANZUP conference highlight, Andrew Weickhardt chats with Betsy Plimack, Chief of the Division of Genitourinary Medical Oncology, Fox Chase Cancer Centre in the US. She talks about the future potential role of genetic mutations in urothelial cancer: can they predict response to treatments or even decide which treatments you should use? They also discuss the use of the new immuno-oncology agents in metastatic kidney cancer: what are the second line options, and how do we measure success of treatments- keep a close ear out for the emerging concept of treatment free survival as the yard stick for the immune-oncology agents.

ANZUP 2019 Interviews - Andrew Weickhardt chats with Betsy Plimack, genetic mutations in bladder ca

Ian Davis

In this ANZUP conference highlight, Andrew Weickhardt chats with Australia’s very own Ian Davis about ANZUP’s successful world leading phase 3 study, ENZAMET. Ian outlines ENZAMET for men with newly diagnosed metastatic hormone naïve prostate cancer and how it differs from the other trials involving second line anti-androgens in this space. Ian also discusses how you might decide between the myriad of treatment options that have now shown effect in the upfront hormone naïve metastatic setting.

ANZUP 2019 Interviews - Andrew Weickhardt talks with Ian Davis about the ENZAMET study